High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer.
about
High dose rate prostate brachytherapy: an overview of the rationale, experience and emerging applications in the treatment of prostate cancerIs robotic arm stereotactic body radiation therapy “virtual high dose ratebrachytherapy” for prostate cancer? An analysis of comparative effectiveness using published data [corrected].Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancerLow-dose-rate or high-dose-rate brachytherapy in treatment of prostate cancer - between options.Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early resultsHematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer.A Report on the Clinical Outcome after High-Dose Rate (HDR) Brachytherapy as Monotherapy in Early Prostate Cancer.PEGylation, increasing specific activity and multiple dosing as strategies to improve the risk-benefit profile of targeted radionuclide therapy with 177Lu-DOTA-bombesin analogues.New advances in focal therapy for early stage prostate cancer.Dosimetric coverage of the prostate, normal tissue sparing, and acute toxicity with high-dose-rate brachytherapy for large prostate volumesHypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer.High dose rate brachytherapy as monotherapy for localised prostate cancer: a hypofractionated two-implant approach in 351 consecutive patients.Propensity score matched comparison of SBRT versus IMRT for the treatment of localized prostate cancer.The emerging role of high-dose-rate (HDR) brachytherapy as monotherapy for prostate cancer.Dosimetric benefits of hemigland stereotactic body radiotherapy for prostate cancer: implications for focal therapy.Hypofractionated stereotactic body radiotherapy in low- and intermediate-risk prostate carcinomaProstate Cancer Radiation Therapy: What Do Clinicians Have to Know?Brachytherapy in the therapy of prostate cancer - an interesting choiceHigh-dose-rate brachytherapy as monotherapy for prostate cancer: technique, rationale and perspective.Evolution of advanced technologies in prostate cancer radiotherapy.Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer?Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancer.Hypofractionation in prostate cancer: radiobiological basis and clinical appliance.A review of rectal toxicity following permanent low dose-rate prostate brachytherapy and the potential value of biodegradable rectal spacers.Brachytherapy: state-of-the-art radiotherapy in prostate cancer.Comparison of patient-reported acute urinary and sexual toxicity scores in a 6- versus 2-fraction course of high-dose-rate prostate brachytherapy monotherapy.Implantable chemotherapy-loaded silk protein materials for neuroblastoma treatment.An evaluation of the robustness of organ-at-risk recommendations made by GEC/ESTRO according to interobserver variability: a single-center experience.Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years.Virtual HDR CyberKnife SBRT for Localized Prostatic Carcinoma: 5-Year Disease-Free Survival and Toxicity Observations.High-dose-rate brachytherapy delivered in two fractions as monotherapy for low-risk prostate cancer.The best method for dose escalation: Prostate brachytherapyProstate cancer high dose-rate brachytherapy: review of evidence and current perspectives.Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy versus conventionally fractionated external beam radiotherapy for low- and intermediate-risk prostate cancer.High dose-rate brachytherapy in the treatment of prostate cancer
P2860
Q26824608-A6AA03ED-78D3-4FD9-8F16-7EC095744491Q30881854-6343B3C1-4425-4AB2-B7C7-45935C13E0F3Q33713059-A7EC08D9-B664-412A-AD1E-DBA6BD20F708Q34342191-5571614A-6849-468E-86DE-299245DFD49CQ34660610-4C3AC932-3FEF-43B3-94FA-9DA8915CAFE5Q35174871-62F69E7E-3CA9-4652-AB2E-0564EED9DD4FQ36062477-0CF7DD33-88E4-4FC9-A5F2-67C23DD0E904Q36338484-0F0818B8-A87D-4BFC-A441-5AB86F459F4EQ36411076-DD8C0B6A-0485-4A06-956F-21484D85B846Q36575937-6B340D2D-2E78-467B-BADA-0372CF133456Q36604355-1A1692F8-0DDC-4CA9-B93F-720EF4F4AD0DQ36898133-5462C8E9-56CC-4A10-A94F-91BC47193EF8Q36969645-963E110E-F024-4154-BBF1-ACBBCA7294F9Q37154093-C5AFD936-C545-4C18-BD3E-37FA9B05D4A5Q37175207-2DD0D995-6732-419E-913B-646BD7D548FDQ37551757-21550B26-53E9-4462-8187-EFDF9D2FCECDQ37578562-29EE267C-C793-4361-81E1-E3D422336ADDQ37601857-92E095CD-93ED-440E-98CD-783B058BFF89Q37730056-2F5EF1CB-624A-4109-94BD-432FCD04AE93Q38135708-8B301DA7-35B1-4619-A491-12D54240DE67Q38152466-1261EF25-7208-4FA1-AD28-F15F4BBF67D3Q38160244-7B6AA636-79A7-4203-8D9C-21B617A02766Q38226822-8B980A98-7040-479C-8DAB-CFC8E5A90DA2Q38357722-01277493-A5C9-4E37-B213-4063588F22B3Q38564059-955613EF-7141-43DE-8172-4125672C0D9EQ38635214-79A37406-BF4D-4554-9C65-52AD155C3D10Q38733843-3574FA9A-41CE-46DC-94D1-C3DE7A53459BQ41061949-AF74514B-4FDF-4F59-814B-7AE5E525EB29Q41895986-7B052C4A-61D0-4032-9D2C-2728698DD69AQ41925779-6B23CDFC-7A9A-4173-B5D6-AD682934AACBQ41952367-044C2645-569F-4541-B82C-EAAB5716E90AQ42183712-55E42FBB-0C5A-4489-A589-274BE98220F8Q48101934-EC4142A4-127A-4B35-BD73-CDFFF9E54AC7Q51614445-8A80058B-C587-491A-9BEA-B82AC70EF007Q57112470-D9CA43C6-820C-4516-80F8-BF051CC8C3BB
P2860
High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
High-dose-rate monotherapy: sa ...... ith localized prostate cancer.
@en
High-dose-rate monotherapy: sa ...... ith localized prostate cancer.
@nl
type
label
High-dose-rate monotherapy: sa ...... ith localized prostate cancer.
@en
High-dose-rate monotherapy: sa ...... ith localized prostate cancer.
@nl
prefLabel
High-dose-rate monotherapy: sa ...... ith localized prostate cancer.
@en
High-dose-rate monotherapy: sa ...... ith localized prostate cancer.
@nl
P2093
P1476
High-dose-rate monotherapy: sa ...... ith localized prostate cancer.
@en
P2093
Alvaro A Martinez
D Jeffrey Demanes
David Brandt
Dennis R Hill
Gary Gustafson
Lionel Schour
Michel Ghilezan
P304
P356
10.1016/J.IJROBP.2010.10.015
P407
P577
2011-02-09T00:00:00Z